BioLife Solutions (BLFS) Stock Forecast, Price & News

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

Is BioLife Solutions a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions or view top-rated stocks.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for BioLife Solutions.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Monday, May, 9th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. BioLife Solutions had a negative trailing twelve-month return on equity of 6.24% and a negative net margin of 10.35%. During the same quarter in the previous year, the company earned $0.01 earnings per share.
View BioLife Solutions' earnings history.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $159.50 million-$171.00 million, compared to the consensus revenue estimate of $165.38 million.

What price target have analysts set for BLFS?

7 Wall Street analysts have issued 12 month price objectives for BioLife Solutions' stock. Their forecasts range from $30.00 to $65.00. On average, they expect BioLife Solutions' stock price to reach $44.50 in the next year. This suggests a possible upside of 258.3% from the stock's current price.
View analysts' price targets for BioLife Solutions or view top-rated stocks among Wall Street analysts.

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:

• Mr. Michael P. Rice, Chairman & CEO (Age 59, Pay $514.71k)
• Mr. Roderick de Greef, Pres & COO (Age 62, Pay $390.89k)
• Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer (Age 50, Pay $407.64k)
• Mr. Todd Berard, Chief Marketing Officer (Age 53, Pay $286.49k) (LinkedIn Profile)
• Ms. Karen Foster, Chief Quality Officer (Age 62, Pay $345.73k) (LinkedIn Profile)
• Mr. Troy Wichterman, Chief Financial Officer (Age 37) (LinkedIn Profile)
• Ms. Sarah Aebersold J.D., VP of Global HR (Age 46) (LinkedIn Profile)
• Mr. Marcus Schulz, Chief Revenue Officer (Age 43) (LinkedIn Profile)

What is Mike Rice's approval rating as BioLife Solutions' CEO?

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioLife Solutions' key competitors?

Some companies that are related to BioLife Solutions include InMode (INMD), Natus Medical (NTUS), Outset Medical (OM), Cutera (CUTR), TransMedics Group (TMDX), ViewRay (VRAY), AxoGen (AXGN), Zynex (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), Hyperfine (HYPR), Stereotaxis (STXS), Electromed (ELMD), Electromed (ELMD) and FONAR (FONR).
View all of BLFS's competitors.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.82%), Vanguard Group Inc. (5.23%), Geneva Capital Management LLC (3.46%), Palisade Capital Management LLC NJ (1.31%), TimesSquare Capital Management LLC (1.14%) and Russell Investments Group Ltd. (1.08%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Aby J Mathew, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends for BioLife Solutions.

Which institutional investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Russell Investments Group Ltd., Victory Capital Management Inc., Dimensional Fund Advisors LP, Palisade Capital Management LLC NJ, Geneva Capital Management LLC, JPMorgan Chase & Co., and Prudential Financial Inc.. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard, and Troy Wichterman.
View insider buying and selling activity for BioLife Solutions or view top insider-selling stocks.

Which institutional investors are buying BioLife Solutions stock?

BLFS stock was purchased by a variety of institutional investors in the last quarter, including Barings LLC, Pier Capital LLC, Gagnon Securities LLC, Zweig DiMenna Associates LLC, BlackRock Inc., Vanguard Group Inc., Qube Research & Technologies Ltd, and RMB Capital Management LLC.
View insider buying and selling activity for BioLife Solutions or or view top insider-buying stocks.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $12.42.

How much money does BioLife Solutions make?

BioLife Solutions has a market capitalization of $526.73 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7.64 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 432 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at (425) 402-1400, via email at [email protected], or via fax at 425-402-1433.